OakChart

Biomea Fusion Inc

BMEAHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

0.6109+0.0639 (11.68%)
2026-11-12 02:10 CET
Market cap
44.28 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-22.31 USD m
Free cash flow, TTM
-43.32 USD m
EPS diluted, TTM
-0.31
P/E
-
Compare

Price

BMEA against its 20, 50 and 200-day averages
2050200beat
0.501.001.502.005.9M11.7MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BMEAclose 0.6120-day 0.6650-day 1.19200-day 1.340.61

72.7% under the 52-week high of 2.24 on 20 Apr 2026. 52-week low 0.54 on 5 Nov 2026. Last 15 sessions, 29.6% high to low

Volume 0.32× normal · the line is the 50-bar volume average

Profile

BMEA
52-week range, 4% of the way up
0.542.24

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in San Carlos, CA.

Employees41
IPOApr 16, 2021
Beta-0.12
ATR, 14d0.09
Rel volume0.32
Short float22.51%
Insider own6.76%
Inst own40.14%

Snapshot

6 groups

Valuation

Index-
Market Cap44.28M
Enterprise Value18.02M
Income-22.31M
Sales0.00M
Book/sh0.10
Cash/sh0.37
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees41
IPOApr 16, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B5.85
P/C1.65
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio2.17
Current Ratio2.17
Debt/Eq0.07
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.31
EPS next Y-0.71
EPS next Q-0.21
EPS this Y43.20%
EPS next Y-6.29%
EPS next 5Y13.75%
EPS past 3/5Y24.92% -46.26%
Sales past 3/5Y- -
EPS Y/Y TTM87.11%
Sales Y/Y TTM-
EPS Q/Q68.92%
Sales Q/Q-
EarningsNov 10 AMC
EPS/Sales Surpr.56.56% -

Ownership

Insider Own6.76%
Insider Trans0.00%
Inst Own40.14%
Inst Trans0.26%
ROA-53.59%
ROE-192.32%
ROIC-294.15%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-7.03%
SMA50-48.57%
SMA200-54.48%
Trades-

Technical

Shs Outstand72.68M
Shs Float67.58M
Short Float22.51%
Short Ratio7.04
Short Interest15.21M
52W High2.24 -72.69%
52W Low0.54 13.11%
Volatility13.51% 12.94%
ATR (14)0.09
RSI (14)33.79
Beta-0.12
Rel Volume0.32
Avg Volume2.16M
Volume694,760

Performance

Perf Week-0.16%
Perf Month-51.52%
Perf Quarter-52.27%
Perf Half Y-58.72%
Perf YTD-50.73%
Perf Year-56.36%
Perf 3Y-92.81%
Perf 5Y-94.80%
Perf 10Y-
Recom1.50
Target Price6.43
Prev Close0.55
Price0.61
Change %11.68%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jan 13, 2026InitiatedRRodman & RenshawBuy$8+1,209.5%
Aug 28, 2025InitiatedJJefferiesBuy$5+718.5%
Jun 03, 2025ResumedPPiper SandlerOverweight$7+1,045.9%
Oct 09, 2024InitiatedEEdward JonesBuy$128+20,852.7%
Sep 27, 2024UpgradeTTruistHold → Buy$54+8,739.4%
Sep 27, 2024UpgradeRRodman & RenshawNeutral → Buy$18+2,846.5%
Aug 29, 2024InitiatedCCapitalOneOverweight$25+3,992.3%
Jun 11, 2024DowngradeTTruistBuy → Hold
Jun 07, 2024DowngradeBBarclaysOverweight → Equal Weight$30 → $5+718.5%
Apr 02, 2024DowngradeJJP MorganOverweight → Neutral$51 → $14+2,191.7%

Peers

Mkt cap
TickerCompanyMkt cap
VTVTvTv Therapeutics Inc84.89M
ALTAltimmune Inc375.41M
GPCRStructure Therapeutics Inc ADR1.49B
CRBPCorbus Pharmaceuticals Holdings Inc77.36M
SEPNSepterna Inc2.31B
KURAKura Oncology Inc687.66M
SNDXSyndax Pharmaceuticals Inc863.37M
VKTXViking Therapeutics Inc3.63B
LXRXLexicon Pharmaceuticals Inc832.59M
SANASana Biotechnology Inc686.16M

Insider trading

4 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Erdtmann Rainer MSee RemarksDec 11 '25Buy1.4330,00042,999723,027Dec 15 04:15 PM
Hitchcock Michael J.M.Interim CEODec 02 '25Buy0.99100,00099,180115,000Dec 04 04:15 PM
Erdtmann Rainer MSee RemarksNov 28 '25Buy1.1040,00044,052683,027Dec 02 04:15 PM
Erdtmann Rainer MSee RemarksDec 01 '25Buy1.0510,00010,500693,027Dec 02 04:15 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M

News

latest 14 of 200
  • Biomea Fusion Reports Third Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire) -8.07% +11.68%
  • Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek 2026 (GlobeNewswire)
  • Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist (GlobeNewswire) -7.35% -33.81%
  • Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist (GlobeNewswire)
  • Biomea Fusion Announces Termination of Proposed Public Offering of Securities (GlobeNewswire) -15.29%
  • Biomea Fusion Announces Proposed Public Offering of Securities (GlobeNewswire)
  • Biomea Fusion to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes (GlobeNewswire) +16.06%
  • Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity (GlobeNewswire)
  • Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire)
  • Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association ("ADA") 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study (GlobeNewswire) -7.30% -9.45%
  • Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity (GlobeNewswire) -5.11%
  • Biomea Fusion to Participate at Upcoming Investor Conferences (GlobeNewswire) -6.33%
  • Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.090-0.207-0.0850.000.007
2026Q22026-08-05-0.120-0.224-0.1150.000.007
2026Q12026-05-11-0.170-0.231-0.1720.000.008
2025Q42026-03-240.038-0.2300.0640.000.007
2025Q32025-11-04-0.270-0.256-0.2740.000.006
2025Q22025-08-05-0.510-0.531-0.5110.000.008
2025Q12025-05-05-0.800-0.612-0.7990.000.005
2024Q42025-03-31-0.810-0.913-0.8080.000.0010
2024Q32024-10-29-0.910-0.945-0.9050.000.0011
2024Q22024-07-31-1.030-1.077-1.0340.000.009
2024Q12024-05-02-1.090-0.994-1.0880.000.008
2023Q42024-04-01-0.980-0.851-0.9730.000.008
2023Q32023-10-30-0.800-0.818-0.7970.000.009
2023Q22023-07-31-0.700-0.861-0.7040.000.009
2023Q12023-05-02-0.980-0.811-0.9820.000.007
2022Q42023-03-28-0.860-0.808-0.8600.000.006

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-0.510--0.1770.00-
2021FY-1.740-1.673-1.4280.000.00
2022FY-2.800-2.742-2.7960.000.00
2023FY-3.440-3.319-3.4380.000.00
2024FY-3.830-3.888-3.8340.000.00
2025FY-1.180-1.532-1.1800.000.00
2026FY--0.670--0.00
2027FY--0.712--0.00
2028FY--0.757--6.19
2029FY--0.915--0.00
2030FY--0.720--0.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-115000.000.000.00
2026Q4S2026-11-105000.000.000.00
2026Q4S2026-08-065000.000.000.00
2026Q4S2026-07-095000.000.000.00
2026Q4S2026-05-126000.000.000.00
2026Q4S2026-05-046000.000.000.00
2026Q4S2026-03-315000.000.000.00
2026Q4S2026-03-264000.000.000.00
2026Q4S2026-03-253000.000.000.00
2026Q4S2025-11-113000.000.000.00
2026Q4S2025-11-103000.000.000.00
2026Q4R2026-11-11200-0.41-0.66-0.16
2026Q4R2026-11-10200-0.41-0.66-0.16
2026Q4R2026-10-21200-0.41-0.66-0.16

Estimate history

EPS, annual-0.04-0.177-1.428-2.796-3.438-3.834-1.183-0.3082
Period2019202020212022202320242025TTM
EPS, quarterly-0.905-0.808-0.799-0.511-0.2740.064-0.172-0.115-0.085
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00000000
Period2019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual30.11830.11829.11529.56235.86735.86772.29972.678
Period2019202020212022202320242025MRQ
Shares, quarterly36.23835.86737.57258.12759.50972.29972.29972.48472.678
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.121.411.754.201.260.950.130.00
Gross Profit-0.12-1.41-1.75-4.20-1.26-0.95-0.130.00
Selling, General and Administrative Excl. Other50.1079.90142.32121.9382.3740.715.201.20
Research and Development34.9161.98118.08102.5562.7128.003.671.09
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-50.22-81.31-144.07-126.14-83.63-41.67-5.33-1.20
Interest Expense0.000.000.000.000.00--0.00
Unusual Expense-29.91-17.650.000.000.000.000.000.00
Net Income Before Taxes-22.31-61.80-138.43-117.25-81.83-41.57-5.32-1.20
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-22.31-61.80-138.43-117.25-81.83-41.57-5.32-1.20
Net Income From Continuing Operations-22.31-61.80-138.43-117.25-81.83-41.57-5.32-1.20
Net Income-22.31-61.80-138.43-117.25-81.83-41.57-5.32-1.20
EPS (Recurring)-0.60-1.42-3.83-3.44-2.80-1.43-0.18-0.04
EPS (Basic, Before Extraordinaries)-0.31-1.18-3.83-3.44-2.80-1.43-0.18-0.04
EPS (Diluted)-0.31-1.18-3.83-3.44-2.80-1.43-0.18-0.04
EBITDA-50.10-79.90-142.32-121.93-82.37-40.71-5.20-1.20
Non-Operating Income (Expense)-2.001.865.648.881.810.100.00-0.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense6.639.5219.0914.1310.346.230.32-
Shares Outstanding72.6872.3035.8735.8729.5629.1230.1230.12
Market Capitalization44.2839.65140.61518.45247.81203.15204.78-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.010.020.050.050.400.500.470.47
Gross Profit-0.01-0.02-0.05-0.05-0.40-0.50-0.47-0.47
Selling, General and Administrative Excl. Other12.9512.7512.7311.6718.2020.7829.2429.61
Research and Development8.539.149.128.1214.4016.5722.9025.24
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-12.96-12.77-12.77-11.72-18.60-21.28-29.71-30.07
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense-6.51-4.120.58-19.862.210.000.000.00
Net Income Before Taxes-6.18-8.33-12.414.61-16.41-20.74-29.26-29.30
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-6.18-8.33-12.414.61-16.41-20.74-29.26-29.30
Net Income From Continuing Operations-6.18-8.33-12.414.61-16.41-20.74-29.26-29.30
Net Income-6.18-8.33-12.414.61-16.41-20.74-29.26-29.30
EPS (Recurring)-0.15-0.15-0.17-0.13-0.25-0.51-0.80-0.81
EPS (Basic, Before Extraordinaries)-0.09-0.12-0.170.06-0.27-0.51-0.80-0.81
EPS (Diluted)-0.09-0.12-0.170.06-0.27-0.51-0.80-0.81
EBITDA-12.95-12.75-12.73-11.67-18.20-20.78-29.24-29.61
Non-Operating Income (Expense)0.270.320.94-3.534.400.540.450.77
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.621.591.581.841.942.573.174.49
Shares Outstanding72.6872.4872.3072.3059.5158.1337.5735.87
Market Capitalization44.28106.28110.6287.67120.21102.6477.19140.61

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments55.8158.28176.87113.05173.5261.700.24
Short Term Receivables0.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets2.2410.052.314.773.040.530.03
Total Current Assets58.0568.33179.18117.82176.5662.220.27
Net Property, Plant & Equipment0.1510.6214.877.995.690.290.00
Total Investments and Advances0.370.370.370.352.230.000.00
Intangible Assets0.00-----0.00
Deferred Tax Assets0.00-3.040.530.62--
Other Assets0.000.622.463.151.230.010.00
Total Assets58.5779.94199.93129.84186.3262.530.27
Short Term Debt Incl. Current Port. of LT Debt1.462.082.470.620.560.260.00
Accounts Payable3.2312.936.856.831.330.730.27
Other Current Liabilities6.416.6613.5411.662.740.630.01
Total Current Liabilities11.1021.6722.8619.104.641.620.29
Long Term Debt0.136.697.831.672.2955.740.00
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities0.00--0.530.62--
Other Liabilities17.790.000.000.000.000.000.00
Total Liabilities29.0228.3630.6921.307.5457.360.29
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity29.5551.57169.24108.54178.785.17-0.02
Total Shareholders Equity29.5551.57169.24108.54178.785.17-0.02
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity29.5551.57169.24108.54178.785.17-0.02
Total Liabilities & Stockholders Equity58.5779.94199.93129.84186.3262.530.27
Book Value Per Share0.411.444.723.676.140.17-0.00
Tangible Book Value Per Share0.411.444.723.676.140.17-0.00
Full-Time Employees41106103835123-
Price to Book Ratio3.271.852.601.901.211.14-
Return on Assets-89.23-98.92-71.11-51.76-33.41-16.96-
Return on Equity-152.35-125.38-84.42-56.96-45.19-206.84-
Return on Invested Capital-208.21-237.58-66.22-74.25-22.96-8.74-
Quick Ratio5.233.157.846.1738.0838.430.93
Current Ratio5.233.157.846.1738.0838.430.93

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-22.31-61.80-138.43-117.25-81.83-41.57-5.32-1.20
Depreciation0.121.411.754.201.260.950.13-
Other Funds (Non Cash)-18.77-6.2921.9314.1310.486.750.320.00
Funds from Operations-40.96-66.67-114.75-98.92-70.09-33.86-4.87-1.20
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-2.36-3.70-5.152.337.67-1.570.41-0.08
Cash from Operating Activities-43.32-70.37-119.89-96.59-62.42-35.44-4.46-1.28
Capital Expenditures0.000.00-0.36-3.37-1.03-3.17-0.050.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.550.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.001.1528.37-30.180.000.00
Purchase of Investments0.000.000.000.000.00-38.490.000.00
Sale Or Maturity of Investments0.000.000.001.1528.378.310.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities0.550.00-0.36-2.2227.34-33.35-0.050.00
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock22.5367.901.67163.801.24153.2265.931.44
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock22.5367.901.67163.801.24153.2265.931.44
Proceedsfrom Stock Options62.7167.750.00161.800.00152.7565.931.44
Issuance or Reduction of Debt, Net0.000.000.000.000.00-0.040.040.00
Change in Long Term Debt0.000.000.000.000.00-0.040.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.00-0.040.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities22.5367.901.67163.801.24153.1965.971.44
Net Change in Cash-20.24-2.47-118.5964.99-33.8484.3961.460.16
Free Cash Flow-43.32-70.37-120.26-99.96-63.45-38.61-4.51-1.28
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments26.7735.1945.0655.8146.6456.22
Short Term Receivables0.000.000.000.000.020.02
Inventories0.000.000.000.000.000.00
Other Current Assets0.891.241.262.242.788.42
Total Current Assets27.6636.4346.3258.0549.4464.66
Net Property, Plant & Equipment0.040.050.070.155.388.13
Total Investments and Advances0.000.000.000.370.370.37
Intangible Assets--0.000.000.00-
Deferred Tax Assets---0.00--
Other Assets0.400.400.000.000.000.00
Total Assets28.1036.8746.3858.5755.1973.16
Short Term Debt Incl. Current Port. of LT Debt0.510.881.241.460.790.76
Accounts Payable3.263.314.613.236.408.38
Other Current Liabilities9.016.303.446.418.388.44
Total Current Liabilities12.7710.489.2911.1015.5617.57
Long Term Debt0.000.000.000.136.096.30
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.00--
Other Liabilities7.7414.2518.3717.7917.9121.79
Total Liabilities20.5124.7427.6729.0239.5745.65
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity7.5912.1418.7229.5515.6227.51
Total Shareholders Equity7.5912.1418.7229.5515.6227.51
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity7.5912.1418.7229.5515.6227.51
Total Liabilities & Stockholders Equity28.1036.8746.3858.5755.1973.16
Book Value Per Share0.100.170.260.410.260.47
Tangible Book Value Per Share0.100.170.260.410.260.47
Full-Time Employees3437404142-
Price to Book Ratio5.855.683.744.724.272.35
Return on Assets-53.59-59.14-88.62-89.23-115.59-107.10
Return on Equity-192.32-164.14-189.44-152.35-209.00-170.54
Return on Invested Capital-81.51-68.62-66.3215.54-75.58-61.34
Quick Ratio2.173.474.985.233.183.68
Current Ratio2.173.474.985.233.183.68

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-6.18-8.33-12.414.61-16.41-20.74
Depreciation0.010.020.050.050.430.47
Other Funds (Non Cash)-4.89-2.531.65-12.99-0.243.02
Funds from Operations-11.07-10.84-10.72-8.34-16.22-17.26
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital2.630.81-0.95-4.854.04-2.08
Cash from Operating Activities-8.43-10.03-11.67-13.19-12.18-19.33
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.550.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.550.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.010.160.0022.362.6039.69
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.010.160.0022.362.6039.69
Proceedsfrom Stock Options0.000.000.0062.710.001.77
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.010.160.0022.362.6039.69
Net Change in Cash-8.42-9.87-11.129.17-9.5820.36
Free Cash Flow-8.43-10.03-11.67-13.19-12.18-19.33

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3022.51%15.2M67.6M2.10M
2026-10-1523.25%15.7M67.6M1.86M
2026-09-3020.83%14.1M67.6M1.50M
2026-09-1519.56%13.2M67.6M1.23M
2026-08-3117.68%11.9M67.6M1.08M
2026-08-1414.53%9.8M67.6M851.16K
2026-07-3114.82%10.0M67.6M986.12K
2026-07-1515.50%10.4M67.4M1.24M
2026-06-3020.52%13.8M67.4M1.45M
2026-06-1520.71%14.0M67.4M1.54M
2026-05-2921.48%14.5M67.4M1.51M
2026-05-1521.36%14.4M67.4M1.49M
2026-04-3021.30%14.4M67.4M1.45M
2026-04-1520.92%14.1M67.4M1.32M
2026-03-3118.96%12.8M67.4M1.22M
2026-03-1318.45%12.2M65.9M1.08M
2026-02-2717.19%11.3M65.9M1.26M
2026-02-1317.17%11.3M65.9M1.33M
2026-01-3015.43%10.2M65.9M1.31M
2026-01-1514.55%9.6M65.9M1.47M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.100.200.154.0829215.000.737-0.0080.000
call1.000.000.050.033.8312020.000.292-0.0070.000
call1.500.000.050.015.48549.000.000.247-0.0090.000
call2.000.000.050.016.2981,3770.000.232-0.0090.000
call2.500.000.750.136.78811.000.000.210-0.0110.000
call5.000.001.000.008.6280.000.000.185-0.0120.000
call7.500.001.000.009.6040.000.000.176-0.0130.000
put0.500.000.100.054.42080.000.00-0.263-0.0080.000
put1.000.001.600.404.1031,4750.00-0.708-0.0070.000
put1.500.651.350.9018.04079.000.00-0.758-0.0090.000
put2.001.052.250.000.0000.000.00-0.778-0.0100.000
put2.500.803.101.900.0002.000.00-0.790-0.0100.000
put5.003.305.600.000.0000.000.00-0.815-0.0120.000
put7.505.808.100.000.0000.000.00-0.824-0.0130.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-10-148-KCurrent report2026-10-13SEC
2026-09-22424B5SEC
2026-09-228-KCurrent report2026-09-22SEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-118-KCurrent report2026-06-10SEC
2026-05-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-118-KCurrent report2026-05-11SEC
2026-04-288-KCurrent report2026-04-27SEC
2026-04-27DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-10SEC
2026-04-27ARSAnnual report to security holders. 2025-12-31SEC
2026-04-034Statement of changes in beneficial ownership of securities2026-04-01SEC
2026-04-034Statement of changes in beneficial ownership of securities2026-04-01SEC
2026-03-2410-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-248-KCurrent report2026-03-24SEC
2026-02-258-KCurrent report2026-02-25SEC
2026-02-17SCHEDULE 13G/ASEC
2026-02-12SCHEDULE 13GSEC
2026-02-06SCHEDULE 13G/ASEC
2026-02-065Annual statement of changes in beneficial ownership of securities2025-12-31SEC
2026-01-148-KCurrent report2026-01-14SEC
2026-01-06S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2025-12-154Statement of changes in beneficial ownership of securities2025-12-11SEC
2025-12-08SCHEDULE 13GSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-12152.68K300
2025-1144.05K100

Institutional holders

Manager% owned
FMR LLC12.16%
VANGUARD CAPITAL MANAGEMENT LLC3.91%
MARSHALL WACE, LLP2.84%
Aisling Capital Management LP2.83%
RENAISSANCE TECHNOLOGIES LLC2.01%
GEODE CAPITAL MANAGEMENT, LLC1.01%
BlackRock, Inc.0.99%
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.85%
Mariner, LLC0.82%
JANE STREET GROUP, LLC0.63%

Funds

Fund% owned
Fidelity Growth Company Fund3.74%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.94%
Fidelity Series Growth Company Fund1.11%
VANGUARD EXTENDED MARKET INDEX FUND0.88%
Select Biotechnology Portfolio0.62%
Fidelity Extended Market Index Fund0.42%
Fidelity Growth Company K6 Fund0.33%
iShares Micro-Cap ETF0.32%
Fidelity Total Market Index Fund0.15%
Goldman Sachs Absolute Return Tracker Fund0.12%

OakChart. BMEA. Cached 15 minutes.